Sign In
Buy IDRSF
$5.75
+0 (+0%)
At Close: Jun 02, 2026
Idorsia Ltd (IDRSF) First Nine-Month 2023 Earnings Call Transcript
05:47am, Wednesday, 25'th Oct 2023
Idorsia Ltd (OTC:IDRSF) First Nine-Month 2023 Earnings Conference Call October 24, 2023 9:00 AM ET Company Participants Andrew Weiss – Senior Vice President, Head of Investor Relations & Corporate C
Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value
01:00am, Tuesday, 24'th Oct 2023
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 24, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2023.
Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023
01:00am, Monday, 23'rd Oct 2023
Allschwil, Switzerland – October 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that it is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023,
Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call
11:45am, Tuesday, 17'th Oct 2023
Idorsia will publish its Nine-Month Financial Reporting 2023 on Tuesday October 24, 2023, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day.
Idorsia reacquires the world-wide rights to aprocitentan
01:00am, Wednesday, 06'th Sep 2023
Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia's oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with resist
Idorsia Ltd (IDRSF) Q2 2023 Earnings Call Transcript
12:53pm, Saturday, 29'th Jul 2023
Idorsia Ltd (OTC:IDRSF) Q2 2023 Earnings Conference Call July 25, 2023 9:00 AM ET Company Participants Andrew Weiss - Head of IR Jean-Paul Clozel - CEO Andre Muller - EVP & CFO Patricia Torr - VP, Hea
Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value
01:00am, Tuesday, 25'th Jul 2023
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25 , 202 3 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2023.
Idorsia announces a cost reduction initiative to be implemented by the end of 2023
01:00am, Friday, 21'st Jul 2023
Ad hoc announcement pursuant to Art. 53 LR In order to give Idorsia the necessary time to realize commercial success – any funds that are raised must be prioritized on activities to maximize their r
Sosei Heptares - Investor and Press Conference on Today's Announcement Regarding the Acquisition and License Transaction with Idorsia
02:31am, Thursday, 20'th Jul 2023
Tokyo, Japan and Cambridge , UK, 20 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), will hold an investor and press conference on today's announcement; “Sosei Heptares Acquires
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – Ju ly 20 , 2023 Idorsia Ltd (SIX: IDIA) today announced the sale of its operating businesses in the Asia Pacific (ex-China) region
Tokyo, Japan and Cambridge, UK, 20 July 202 3 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that it has resolved, at a meeting of the Board of Directors held on 20 July 2023, to
Invitation to Idorsia's HY 2023 Financial Results webcast and conference call
11:45am, Tuesday, 18'th Jul 2023
Idorsia will publish its half year financial results 2023 on Tuesday July 25, 2023, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day.
Idorsia: The Market Has Overreacted
03:57pm, Wednesday, 08'th Feb 2023
Idorsia reported the yearly results for 2022 with some very positive developments, while also discussing important risk factors. Clazosentan will not see the US and the EU market but could be allowed
Idorsia Ltd (IDRSF) Q4 2022 Earnings Call Transcript
02:44pm, Tuesday, 07'th Feb 2023
Idorsia Ltd (OTCPK:IDRSF) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company Representatives Jean-Paul Clozel - Chief Executive Officer André Muller - Chief Financial Officer Simon
Idorsia: Interesting Swiss Biotech, But Commercialization Seems Uncertain
06:06am, Saturday, 04'th Feb 2023
Idorsia is a Swiss biopharmaceutical company with multiple commercial and pre-commercial assets. Idorisa's lead asset Daridorexant seems to be a more attractive option compared to SOC in Isomnia due t
